TFX NYSE
Credit Risk of going bust: higher than 52% of companies Debt: 33.1% of company value Bonds: $146.4M held by 149 funds, 136 bp over Treasuries → details ▾
If the stock fell to about $5.04 (down 96%), Teleflex Incorporated would be worth roughly what it owes.
Total debt $2.87B against a stock market value of $5.80B.
Distance to default 4.95 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.45B (short-term plus half of long-term), stock volatility 39.9%; Altman Z 1.98. A ranking and a back-test, not a forecast.
Bond figures are fund-reported marks (SEC N-PORT) as of Jul 2026. How these are computed.
Wayne, PA 19087-1603
US
Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Salmon Sean | A-Award | 674 | — | 2026-09-08 |
| Salmon Sean | A-Award | 4,444 | $137.00 | 2026-09-08 |
| Salmon Sean | 0 | — | 2026-09-08 | |
| Weidman Jason R. | A-Award | 53,983 | — | 2026-06-08 |
| Weidman Jason R. | A-Award | 26,071 | $131.74 | 2026-06-08 |